@article{article, title = {{Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinibvs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data}}, publisher = {{Anticancer Research USA Inc.}}, url = {{https://doi.org/10.21873/anticanres.16809 }}, year = {{2023}}, month = {{12}}, author = {{MOSER SS and APTER L and SOLOMON J and CHODICK G and WOLLNER M and SIEGELMANN-DANIELI N}}, doi = {{10.21873/anticanres.16809}}, volume = {{44}}, journal = {{Anticancer Research}}, issue = {{1}}, pages = {{257-265}}, note = {{Accessed on 2025/08/13}}}